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Intestinal constipation in intensive care units
Constipação intestinal em terapia intensiva
INTRODUCTION 
Constipation is an unusual subject in intensive care journals and text-
books. Nevertheless, it is a complication commonly identified among critical-
ly ill patients. These are more prone to constipation for a number of factors, 
including: confinement to the bed, use of sedatives and opioids, neuromus-
cular blockers, vasopressors, inflammatory mediators, shock, dehydration and 
electrolyte disturbances, among others.(1-2) 
The incidence of constipation in patients in intensive care units (ICUs) 
vary widely in literature, between 5% and 83%.(1-5) This can be attributed 
to lack of a specific definition for the critically ill patient. In its guidelines, 
the American Gastroenterological Association defines constipation as the fre-
quency of feces evacuation of less than 3 times a week, feeling of incomplete 
rectal evacuation, hard stool, struggling to pass stools and need to tap for 
rectal emptying.(6) These criteria, known as the Rome criteria, are not very 
practical therefore not often used with critically ill patients. 
Although the intensivist physician often faces the problem, the approach 
to critically ill patients remains unclear. In a survey by Mostafa et al. in 2003, 
these authors, by means of questionnaires sent to 143 ICUs, found that in 
52% of units, constipation was recognized as a problem. However, only 3.5% 
of ICU had protocols for diagnosis and treatment.(1) 
Constipation can lead to complications such as abdominal distension, 
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ABSTRACT
Constipation is a common com-
plication identified among critically ill 
patients. Its incidence is highly vari-
able due to lack of definition of such 
patients. Besides the already known 
consequences of constipation, in recent 
years it was observed that this com-
plication may also be related to worse 
prognosis of critically ill patients. This 
review endeavors to describe the main 
available scientific evidence showing 
that constipation is a prognostic marker 
and a clinical representation of intesti-
nal dysfunction, in addition to eventu-
ally interfering in the prognosis with 
treatment. Ogilvie syndrome, a major 
cause of morbidity and mortality in 
intensive care units was also reviewed. 
Considering the above cases it was con-
cluded that more attention to this dis-
order is required in intensive care units 
as well as development of protocols for 
diagnosis and management of critically 
ill patients.
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vomiting, restlessness, intestinal obstruction and per-
foration and others, still poorly elucidated.(7) Recent 
studies have identified constipation as an independent 
prognostic factor in the evolution of critically ill patients 
and demonstrated that treatment can result in better 
prognosis.
Intestinal constipation as a marker of severity 
In addition to previously known implications of 
constipation, studies published in the last decade have 
shown that constipation can be associated with poor out-
come of patients admitted to intensive care units (Chart 
1). In 2003, Mostafa et al. studied 48 patients consecu-
tively admitted over a period of 3 months in a mixed 
intensive care unit, receiving enteral nutrition, mechani-
cal ventilation and with an expected ICU stay of at least 
3 days. They observed a statistically significant relation-
ship between weaning failure from mechanical ventila-
tion and constipation. For patients with an over-3day 
stay, without a bowel movement, frequency of weaning 
failure was 17 of 40 patients, while among 8 patients 
without constipation there was no weaning failure from 
mechanical ventilation (p <0.05).(1) Van der Spoel et al. 
in 2006 published a study confirming some findings of 
the Mostafa study, showing an increase in the duration 
of mechanical ventilation among patients who remained 
constipated for more than 6 days in the ICU. Mechani-
cal ventilation time in the early evacuation group (within 
the first 6 days in the ICU) was 10.9 days versus 19.2 
days for the late evacuation group (only after 6 days in 
ICU), p = 0.018. Moreover, this study showed shorter 
stay of patients who had early evacuation (12.6 days x 
21.4 days, p = 0.017) and positive correlation between 
days with no evacuation and no increase in the Sequen-
tial Organ Failure Assessment (SOFA) score. Another 
interesting result is that approximately 50% of patients 
had not evacuated by the 6th day after admission to the 
ICU. It is noteworthy that this study had a protocol for 
treatment of constipation, including administration of 
lactulose and phosphate enemas to patients that after the 
3rd rd day of stay had not evacuated.(4) 
In an observational study conducted in Brazil, Nassar 
et al. studied constipation in patients with 3 or more days 
in an intensive care unit. Constipation was defined as fail-
ure to eliminate feces for 3 consecutive days. The study 
included 106 patients and incidence of constipation in 
this cohort was 69.9%. In this study, constipation was not 
related to any of the prognostic variables studied, namely: 
renal replacement therapy, days free of mechanical ventila-
tion, length of ICU stay, ICU mortality and hospital mor-
tality. Two other interesting findings of this study were in 
multivariate analysis, the association between early initia-
tion of enteral nutrition and low incidence of constipation 
and no association between use of opioids and a higher 
incidence of this complication.(5)
Based upon these data, constipation may be linked 
to prognosis of critically ill patients. However, a new 
question arises: would intestinal constipation be only a 
marker of severity or the clinical manifestation of an or-
gan dysfunction that must be diagnosed and treated in 
Chart 1- Studies relating intestinal constipation and prognosis in critically ill patients
Studies N
Prognostic variables
SOFA Mechanical ventilation Length of stay Mortality
Mostafa, 2003 48 Not analyzed
Larger number of weaning 
failures among constipated 
patients
No difference No difference
van der Spoel, 
2006 44 
Less among patients 
that passed stool be-
fore the 6th day of 
ICU stay
Shorter mechanical venti-
lation time among patients 
that passed stool before the 
6th day of ICU stay
Shorter length of stay 
among patients that pas-
sed stool before the 6th 
day in the of ICU 
Not analyzed
van der Spoel, 
2007 308 Not analyzed Not analyzed
Shorter length of stay 
among patients receiving 
lactulose
Multivariate analyses identi-
fied APACHE II and time to 
produce stool as independent 
variables predictors of morta-
lity 
Nassar, 2009 106 Not analyzed
No difference between 
groups in relation to venti-
lation-free days in 28 days.
No difference No difference
N – number of patients; SOFA – Sequential Organ Failure Assessment; ICU – intensive care unit; APACHE – Acute Physiologic Chronic Heatlh
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order to modify prognosis of these patients?
Constipation: a marker of severity or organ dys-
function to be treated? 
In a new study published in 2007, van der Spoel et al. 
again address the issue of constipation. The purpose this 
time was to establish whether lactulose and polyethylene 
glycol are effective purgatives when compared to placebo 
and also whether patients who used these medications 
for treatment of constipation showed some prognostic 
benefit. This study, double-blind, randomized, con-
trolled, with 308 individuals, included patients who did 
not evacuate until the 3rd day of ICU and were diagnosed 
with multiple organ dysfunction receiving hemodynamic 
support and mechanical ventilation. The authors showed 
the effectiveness of lactulose and polyethylene glycol 
to promote evacuation when compared to the placebo 
group. There was no statistical difference between the 
lactulose and polyethylene glycol (PEG) groups regard-
ing effectiveness in promoting bowel movement. There 
were also shorter ICU stays in the group that made use 
of lactulose when compared with the placebo group (156 
hours x 196 hours, p = 0.016) and a tendency to re-
duce length of the PEG group (190 hours x 196 hours, 
p = 0.6). In patients who evacuated by the 6th day of 
hospitalization, length of ICU stay was a mean of 148 
hours against 261 hours in the group who evacuated af-
ter the 6th day (p = 0.01). Multivariate analysis identi-
fied the Acute Physiologic Chronic Health Evaluation II 
(APACHE II) score and time for fecal production (time 
between ICU admission and the first evacuation) as the 
independent predictors of mortality.(2)
How could intestinal constipation affect prognosis 
of critically ill patients?
Constipation could potentially affect prognosis of 
critically ill patients in many ways. They can be classi-
fied as: mechanical, nutritional and infectious causes. 
Mechanical causes   
Abdominal distension may hinder action of the dia-
phragm, reducing lung compliance and increased respi-
ratory effort.(2) In some patients, it may be related to in-
creased intra-abdominal pressure (IAP).(8-9) IAP increase 
reduces lung compliance; increases pleural and intratho-
racic pressure, and may cause edema and atelectasis. 
Patients presenting intra-abdominal hypertension syn-
drome may require a higher positive end expiratory pres-
sure (PEEP) to offset the effects of increased IAP. That is 
why, intestinal constipation could be related to increased 
duration of mechanical ventilation.(8,10-11)
Nutritional causes 
Intestinal constipation may represent one facet of 
a major condition, dysfunction of intestinal motility. 
Patients who develop constipation often concomi-
tantly present with gastroparesis and ileoparesia that 
delay the onset and hinder progression of nutritional 
support. These patients may delay or even not meet 
the nutritional target intended for the enteral route. 
Inadequate nutrient intake leads to a worse prognosis 
because it reduces muscle strength and overall func-
tional capacity(12) lessens the capacity to synthesize 
new tissue and wound healing(13-14) increase the num-
ber of infections(15) as well as increases length of stay 
and morbidity and mortality.(16-17)
Bacterial translocation 
The digestive system, besides its function to absorb nu-
trients, plays an important role in defending the organism. 
The intestinal barrier protects the organism against thou-
sands of anaerobic microorganisms, gram-positive, gram-
negative and antigens coming from food. This barrier com-
prises the Peyer plaques which constitute approximately 
70% of the organism’s lymphoid tissue and also isolated 
lymphocytes. Through a series of systems functioning to-
gether, the intestinal barrier maintains homeostasis.(18) M 
cells of the intestinal mucosa serve as an access- portal to 
antigens allowing them to reach the antigen-presenting 
cells, particularly dendritic cells of the Peyer plaques. The 
intestinal mucosa epithelial cells may also, by means of 
endocytosis and binding of MHC class proteins, present 
the processed antigen on intraepithelial lymphocytes or 
lamina propria lymphocytes, or directly on dendritic cells 
of Peyer’s plaques. Among the intestinal mucosa cells and 
structures that maintain the physical and functional in-
tegrity of mucosal as tight junctions were found.(19) The 
dendritic cells can, by their dendrites, contact antigens 
through these structures.(20) By means of all these paths, 
the lymphoid system maintains organic integrity. 
However, in some situations antigens and microor-
ganisms may break this barrier, a process called bacterial 
translocation.(21) Inflammatory mediators can increase 
intestinal permeability without necessarily damaging the 
mucosa. Cytokines may act as modulators of these struc-
tures and may thus increase permeability to antigens that 
promote onset of an intestinal inflammatory cascade.(18) 
Some in vitro studies have shown that TNF-α, IFN-y, 
IL-4, IL - 3 increase permeability of the intestinal barri-
er. The mechanism is not yet fully understood, however, 
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it is known that TNF-α and IFN-y change the phospho-
rylation of myosin light chain, thereby disrupting the 
cytoskeleton, morphological changes and redistribution 
of the tight junctions. These cytokines also induce pro-
duction (in enterocytes, of immune cells and commensal 
bacteria) of nitric oxide synthase (iNOS) in the intestine. 
Increased production of iNOS leads to reduced produc-
tion of ATP and disorganization of the cytoskeleton of 
intestinal mucosa cells.(18-19) 
Two theories, not mutually exclusive, seek to explain 
the process of breaking the intestinal barrier: 
A. “The three hit model” - model of the three insults: 
bacterial translocation is the result of two initial insults. 
The first insult (which may be trauma, surgery or other) 
leads to splanchnic hypoperfusion. The second insult oc-
curs after adequate resuscitation and results in ischemia 
and reperfusion, with consequent increase of intestinal 
permeability. In the final insult, bacteria and cytokines 
affect local immunological and systemic factors sustain-
ing the inflammatory state, bringing about systemic in-
flammatory response syndrome (SIRS) and multiple or-
gan dysfunction (MODS).(22) 
B. “Gut-lymph theory” - theory of the intestinal lym-
phoid tissue: macrophages and mesenteric lymph nodes 
block the majority of translocated bacteria. Some survive 
or release endotoxins, which through the intestinal lym-
phatic system migrate to the thoracic duct and thereby 
to the right-side circulation reaching the lung. Activa-
tion of alveolar macrophages contributes to progression 
of pulmonary dysfunction and MODS.(18)
However, confirmation of these theories about exis-
tence of bacterial translocation still lacks corroboration 
in clinical studies. 
Factors that predispose to translocation are intestinal 
obstruction, jaundice, inflammatory bowel disease, cancer, 
pre-operative parenteral nutrition, emergency surgery and 
gastric colonization by microorganisms.(21) Several studies 
have shown an association between dysfunction of intesti-
nal motility and bacterial proliferation.(23-26) In an experi-
mental study Nieuwenhuijs et al. compared infusion of 
morphine with placebo. Significant changes of intestinal 
motility were recorded in the group receiving morphine. 
Further, in cultures of the duodenum this group showed 
increased growth of anaerobics and Gram-positive (p 
<0.05) and Gram-negative (p = 0.08).(27) However, there 
is little evidence relating hyper-proliferation caused by 
motility dysfunction to intestinal bacterial translocation. 
Bacterial hyper-proliferation can lead to an increase of en-
dotoxin, with a possibly increased intestinal permeability 
and translocation.(28) 
As such, intestinal constipation could be related to 
bacterial hyper-proliferation, intestinal mucosa injury 
and translocation of bacteria by the damaged mucosa. 
Treatment of constipation could therefore result in bet-
ter prognosis for the critically ill by reducing occurrence 




Intestinal constipation can also result from severe 
Ogilvie’s syndrome or colonic pseudo-obstruction syn-
drome. A dilation of the cecum and right colon in the 
absence of mechanical obstruction occurs in this syn-
drome. It was described in 1948 by William Ogilvie in 
two patients with colon paresis caused by retroperito-
neum neoplasms with invasion of the celiac plexus.(29) 
Its incidence is not well established in literature. It is 
an important cause of morbidity and mortality in ICU 
patients,(30-31) and in presence of intestinal perforation, 
mortality can exceed 50%.(31) It is caused by imbalance of 
the autonomic activity with parasympathetic suppression 
and increased sympathetic activity. Interruption of the 
autonomic nerves activity, from S2 to S4 leaves the distal 
colon sluggish and the proximal colon functioning.(30-32) 
This may be caused by electrolyte disturbances, mostly 
hypocalemia, hypocalcemia and hypomagnesemia. The 
clinical condition may be represented by: abdominal 
distention (100%), abdominal pain (80%) and nausea/
vomiting (60%). Patients reported passage of flatus and 
/ or stool in 40% of cases. There may be bowel sounds 
in 70% of cases.(30,33) Distension develops for 3 to 7 days, 
but can occur in less than 24 hours.(31) The differential 
diagnosis includes mechanical obstruction and mega-
colon due to Clostridium difficile.(31) Colonic distension 
should be confirmed by simple abdominal X-ray and 
mechanical obstruction should be discarded by comput-
ed tomography (Figures 1 and 2). The treatment assess-
es signs of impending or already installed perforation. 
Once these warning signs are discarded, a conservative 
management in the first 24 to 48 hours may be the best 
choice. During this period, possible causes should be re-
dressed, and relief, measures undertaken such as a gastric 
probe. If improvement is not achieved neostigmine (2 to 
2.5 mg intravenously over 3 to 5 minutes) may be used 
and the patient monitored, with atropine available at the 
bedside. The patient must be constantly monitored and 
under surveillance for at least 30 minutes after infusion 
of neostigmine.(31-32) If desired effects are not achieved 
with these measures, or in case of recurrence, decompres-
sion via colonoscopy may be attempted and, ultimately 
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surgery or percutaneous decompression.(31,34) 
Figure 1- Computed tomography (panoramic) of the abdo-
men of patient with Ogilvie syndrome showing acute colon 
distension, including cecal dilatation of 13.6 cm.
Figure 2 – Computed tomography showing colon-dilatation 
in patient with Ogilvie Syndrome.
Treatment of intestinal constipation
Some experimental studies illustrate the possible rela-
tionship between treatment of intestinal constipation and 
bacterial translocation. Ozaslan et al. evaluated 50 Wistar 
mice that were divided into 10 controls, 20 submitted to 
ligature of the common biliary duct plus enteral admin-
istration of 2ml/day lactulose and 20, only submitted to 
common biliary duct ligature. The primary objective was 
to detect presence of Escherichia coli in mesenteric lymph 
nodes and cecum of these animals. As a result, a reduction 
in bacterial translocation in the group receiving lactulose 
(2 / 20 when compared with 8 / 20, p = 0.06) was found. 
There was also a reduction of translocation of other gram-
negative bacteria (p <0.01).(35) 
Another study that also supports the above was 
performed in 45 guinea pigs divided as follows: 15 in 
the surgical control group, 15 in the group of surgery 
trauma receiving 0.9% saline by gavage and 15 in the 
group receiving surgery trauma lactulose by gavage. The 
purpose was to identify bacterial translocation to mes-
enteric lymph nodes. A statistically significant reduction 
from enteric translocation to lymph nodes in the lactu-
lose group was detected. Furthermore, in the mecum of 
the lactulose group animals, an increased count of lac-
tobacilli and a reduced number of gram- negative and 
anaerobic bacteria was detected as well as an increased 
thickness of the intestinal mucosa.(36) 
Several laxative medications are available that can be 
classified according to their action mechanism: 
- Bulk-forming laxatives (psyllium, polycarbophil, 
methylcellulose) 
- Lubricating agents (mineral oil) 
- Stimulants: 
- surfactants (Ducusate, biliary acids); 
- diphenylmethane derivatives (phenolphthalein, bi-
sa codyl, sodium picosulphate); 
- ricinoleic acid (castor oil); 
- anthraquinones (senna, cascara sagrada, aloe, rhu-
barb); 
- osmotic agents (salts of magnesium and phosphate, 
lactulose, sorbitol, polyethylene glycol); 
- glycerin suppositories; 
- phosphonate and glycerine enemas. 
In one of his studies, van der Spoel et al. tested the 
efficacy of lactulose and polyethylene glycol comparing 
one to the other and the placebo in a group of critically 
ill patients. In this study a similar efficacy was described 
for both drugs and both were statistically superior to 
placebo in promoting bowel movement.(2) Lactulose is 
described in other protocols for treatment of intestinal 
constipation.(4) Senna, an anthraquinone, is also de-
scribed in a treatment protocol.(7) Enemas are generally 
reserved for patients unresponsive to enteral drug ad-
ministration.(2,4,7) There is no evidence described for the 
advantage of phosphonate enemas or enemas glycerine. 
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In terms of prevention, the relationship between con-
stipation and use of opioids is well known, especially 
morphine. Opioids can cause intestinal constipation 
primarily through direct action on specific receptors in 
the myenteric plexus.(37) Daily interruption of sedation 
and of non-medicinal comfort measures may reduce use 
of these drugs, thus reducing incidence of constipation 
among patients who require sedation and analgesia. Opi-
oid antagonists, such as oral naloxone(38) or oral meth-
ylnaltrexone,(37) can also be used to mitigate the effects 
on intestinal motility. Furthermore, the fact that consti-
pation may cause pain demands attention because if pain 
is not identified it may increase consumption of opioids 
and sedatives to ameliorate patient comfort and contrib-
ute to perpetuation of the condition. 
Clinical implications 
The reasons given in this review suggest that intesti-
nal constipation in addition to being a marker of prog-
nosis can be an organic dysfunction to be diagnosed 
and treated. Although it is not known whether there is 
a causal relationship between occurrence and generation 
of more dysfunction, perhaps treatment may contribute 
to a better prognosis of critically ill patients in intensive 
care units. 
There are no clear guidelines for management of con-
stipation in intensive care units. Based upon experience 
of important studies on the subject, a few points are sug-
gested 
1. Intensive care units should establish protocols for 
the identification, quantification and treatment of con-
stipation.(1,7) 
2. Diagnosis of intestinal constipation of critically 
ill patients should be based on frequency of stools be-
cause it is easier to record and understanding for medical 
and nursing staff. If possible, also record the estimated 
amount and appearance.(7) The Bristol scale (Bristol 
Stool Form Scale) is used to standardize the appearance 
of feces. Its use has been already described in diagnostic 
protocols and treatment of constipation in critically ill 
patients. This scale presents pictures and description of 
the appearance of stool and a number that represents the 
classification category of stools.(7,39) 
3. The team responsible for the care of the patient 
should be aware of onset and early progression of diet, 
using wherever possible the enteral route. Diets meeting 
the patient’s need of fibers are also useful to prevent de-
velopment of constipation.(5,7) 
4. The team must be aware of conditions that favor 
occurrence of intestinal constipation, such as prolonged 
immobilization, use of opioids, excessive sedation, neu-
romuscular blockers, dehydration, electrolyte imbalance, 
shock, and others, always attempting to minimize expo-
sure to these conditions and begin specific therapy when 
intestinal constipation is foreseen or in the presence of 
risk factors.(7)
In summary, intestinal constipation is a common 
complication in critically ill patients. Among causes of 
constipation, Ogilvie syndrome must be emphasized. 
Constipation can be related to prognosis of critically ill 
patients and thus represents a clinical manifestation of 
intestinal dysfunction. As such it has to be diagnosed 
and treated. More studies are required on the subject to 
warrant drafting of guidelines for diagnosis and manage-
ment of this complication.
RESUMO
A constipação intestinal é uma complicação comumente 
identificada entre pacientes graves. Sua incidência é bastante vari-
ável devido à carência de uma definição aplicável a estes pacientes. 
Além das consequências já conhecidas da constipação, nos últimos 
anos tem-se percebido que essa complicação também pode estar 
relacionada ao pior prognóstico de pacientes críticos. Ao longo 
desta revisão procurou-se descrever as principais evidências cientí-
ficas disponíveis mostrando ser a constipação um marcador prog-
nóstico e uma das representações clínicas da disfunção intestinal, 
além da possibilidade de interferir no prognóstico com o trata-
mento. Revisou-se também a síndrome de Ogilvie, importante 
causa de morbidade e mortalidade nas unidades de terapia inten-
siva. Conclui-se, por todo o exposto, ser necessária mais atenção 
a esse distúrbio nas unidades de terapia intensiva, com elaboração 
de protocolos de diagnóstico e manejo em pacientes graves.
Descritores: Constipação intestinal; Pseudo-obstrução co-
lônica; Cuidados críticos; Cuidados intensivos; Mobilidade gas-
trointestinal 
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